Trividia Health Correction for TRUE METRIX Blood Glucose Monitoring Systems
Trividia Health, Inc. issued an update to a previously announced medical device labeling correction regarding several models of TRUE METRIX Blood Glucose Monitoring Systems. This update follows an initial correction notice issued by the company on February 6, 2026.
This affects Trividia Health, Inc., users of TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO systems, and healthcare professionals managing diabetic patients using these monitors.
The issuance of an update to a prior labeling correction suggests that initial remediation efforts may have required further clarification or expansion to ensure user safety and device efficacy. For regulatory professionals, this underscores the importance of precise labeling and the potential for phased corrective actions when addressing post-market device issues. The reliance on labeling updates indicates a need for clear communication regarding device operation or hazard mitigation.
Quality and Regulatory teams should verify that existing inventory and distributed units of TRUE METRIX systems reflect the updated labeling. Compliance departments should ensure that previous correction notices from February 2026 have been fully integrated into current risk management files.
FT. LAUDERDALE, FL – May 1, 2026 – Trividia Health, Inc., a global leader in diabetes management, today provided an important update to the medical device labeling correction it announced on February 6, 2026, for all TRUE METRIX®, TRUE METRIX® AIR, TRUE METRIX® GO, and TRUE METRIX® PRO Blood Glucose
Open in openFDA / FDA.gov